Designing and Executing Basket Trials Using Genetic Markers

Introduction to Basket Trials in Oncology

Basket trials represent a paradigm shift in oncology trial design. Instead of recruiting patients based solely on tumor histology (e.g., lung, breast, colorectal), basket trials enroll patients who share a common genetic alteration across multiple tumor types. For example, a trial may test a BRAF inhibitor in any solid tumor harboring a BRAF V600E mutation, regardless of whether it originated in the thyroid, lung, or colon.

This approach supports the concept of tumor-agnostic therapy—where the drug’s indication is defined by the biomarker rather than the cancer’s site of origin. The FDA has already approved multiple tumor-agnostic indications, such as pembrolizumab for microsatellite instability-high (MSI-H) tumors and larotrectinib for NTRK fusions.

Basket trials are especially valuable for rare mutations, where traditional histology-specific trials would take years to accrue enough patients. By pooling patients across cancers, basket trials accelerate development timelines and enable smaller, more focused studies.

Regulatory Perspective on Basket Trials

Regulatory agencies recognize the value of basket trials but expect robust scientific rationale and statistical design. The FDA’s 2019 guidance on enrichment strategies emphasizes that basket trials should pre-specify the biomarker, inclusion/exclusion criteria, and statistical plan for each tumor type cohort. If efficacy varies significantly between histologies, tumor-specific labeling may be required rather than a broad tumor-agnostic claim.

The EMA requires similar rigor and recommends using adaptive statistical models to address variability in treatment effect. Under the new EU Clinical Trials Regulation (CTR), multinational basket trials must clearly define how genetic testing is performed and validated across all participating sites.

Examples of regulatory success include the Vitrakvi (larotrectinib) approval based on pooled efficacy data across 17 tumor types with NTRK fusions, and the approval of entrectinib with combined data from multiple basket studies targeting ROS1-positive NSCLC and NTRK fusion-positive tumors.

Designing a Basket Trial: Step-by-Step

Designing a basket trial requires careful alignment between scientific, regulatory, and operational teams. The typical workflow includes:

1. Identify the Target Genetic Marker: Select a biomarker with strong preclinical and/or early clinical evidence of drug sensitivity.
2. Validate the Diagnostic Assay: Use an FDA-approved or analytically validated NGS or PCR-based assay to confirm biomarker status. Parameters like LOD (e.g., 1% VAF for ctDNA detection) and LOQ must be pre-specified.
3. Define Cohorts: Create separate cohorts for each tumor type or relevant clinical context. Example: Cohort A—BRAF V600E colorectal cancer; Cohort B—BRAF V600E thyroid cancer.
4. Statistical Plan: Decide whether each cohort will be analyzed independently or in a pooled manner. Bayesian hierarchical models can borrow information across cohorts to improve power.
5. Adaptive Features: Include interim analyses to drop non-responsive cohorts or expand promising ones.

A dummy table for a hypothetical BRAF basket trial could look like this:

Operational Considerations: Biomarker Testing and Turnaround

Fast and accurate biomarker testing is critical to basket trial success. A delay in obtaining NGS results can lead to patient drop-off or missed treatment windows. Many sponsors use central laboratories for uniformity, but decentralized testing at local labs may be necessary for rare mutations with urgent treatment needs. In either case, cross-validation of local and central assays is essential, with ≥90% concordance required for regulatory acceptability.

Informed consent must explicitly describe genetic testing, data sharing, and potential incidental germline findings. Moreover, trial teams should prepare SOPs for genetic data handling in compliance with GDPR in the EU and HIPAA in the US.

For best practices in trial SOP creation, resources from PharmaSOP.in offer practical templates adapted to biomarker-driven studies.

Real-World Example: NTRK Fusion Basket Trials

Larotrectinib’s basket trials are a textbook example. By enrolling patients with NTRK fusions across 17 tumor types and pooling the data, the sponsor demonstrated a 75% ORR with durable responses, leading to tumor-agnostic approval. The trial incorporated rigorous confirmatory testing of NTRK fusion status, standardized imaging assessments, and patient-reported outcomes as secondary endpoints.

One key regulatory takeaway: durability of response was critical for approval, as median duration exceeded 9 months in most tumor types. This long-term follow-up data was essential to justify a tumor-agnostic claim rather than multiple tumor-specific approvals.

Conclusion: The Future of Basket Trials

Basket trials have transformed oncology drug development, enabling faster access to targeted therapies for patients with rare genetic alterations. Success hinges on selecting robust biomarkers, validating assays, designing statistically sound and adaptive trials, and meeting regulatory expectations for multi-cohort data interpretation.

As molecular profiling becomes standard of care, basket trials will likely expand beyond oncology into rare genetic diseases, leveraging the same precision medicine principles. The ability to demonstrate benefit across diverse patient populations, regardless of tumor origin, positions basket trials as a cornerstone of next-generation clinical research.

Integrating Companion Diagnostics into Precision Oncology Trials

What Are Companion Diagnostics and Why They Matter

Companion diagnostics (CDx) are in vitro diagnostic devices or imaging tools essential for the safe and effective use of a corresponding therapeutic product. In oncology, CDx testing is often the gateway to trial enrollment—patients must meet specific biomarker-defined eligibility criteria before receiving the investigational drug. For example, a HER2-targeted therapy requires HER2 amplification confirmation, an EGFR inhibitor needs exon 19 deletions or L858R mutations, and an ALK inhibitor demands ALK rearrangement detection.

The role of CDx is not only to identify patients most likely to benefit but also to exclude those at higher risk of adverse effects. Regulators like the FDA and EMA mandate that, when biomarker-based eligibility is critical, the diagnostic must be validated to the same standard of evidence as the drug itself. This concept is central to precision oncology: the therapy’s approval can be contingent on having an approved CDx available.

Real-world example: Trastuzumab deruxtecan was approved alongside a specific HER2 testing method with defined scoring cutoffs. Without an approved HER2 IHC or ISH assay, trial enrollment would not have been possible. Similarly, osimertinib’s label specifies that only EGFR T790M-positive patients by an FDA-approved test are eligible post-EGFR-TKI resistance.

Regulatory Expectations: FDA, EMA, and Global Considerations

From a regulatory standpoint, companion diagnostics are considered high-risk (Class III in the US, Class C under IVDR in the EU) because incorrect results can lead to inappropriate treatment. The FDA’s guidance “In Vitro Companion Diagnostic Devices” specifies that CDx must demonstrate both analytical and clinical validation. Analytical validation ensures that the assay reliably and reproducibly measures the biomarker; clinical validation confirms the biomarker’s predictive value in identifying patients who will benefit from the therapy.

In the EU, under the IVDR (Regulation (EU) 2017/746), companion diagnostics must be assessed by a notified body and involve consultation with a competent medicines authority, such as the EMA. This adds complexity and timelines, especially for global oncology trials seeking simultaneous approval in multiple jurisdictions. Countries like Japan, China, and Australia have their own specific regulatory frameworks, and harmonizing CDx approvals can be a major operational challenge.

One frequent pitfall in global trials is assuming that a US-approved CDx automatically meets EU or APAC requirements—it often does not. This requires early regulatory strategy alignment between drug and diagnostic development teams, ideally before pivotal trial protocol finalization.

Analytical Validation: Establishing Assay Performance (LOD, LOQ, and More)

Analytical validation parameters for CDx include sensitivity, specificity, limit of detection (LOD), limit of quantitation (LOQ), reproducibility, and robustness. For example, a ctDNA-based assay for detecting EGFR T790M may need an LOD of 0.2% variant allele frequency (VAF) with ≥95% confidence to ensure that eligible patients are not missed. LOQ might be set at 0.5% VAF to ensure reliable quantitation for therapy decision-making.

For cross-contamination risk in diagnostic reagent preparation, applying pharmaceutical cleaning validation concepts like MACO (Maximum Allowable Carryover) and PDE (Permitted Daily Exposure) ensures that no assay-to-assay contamination occurs in multi-test platforms.

Designing Clinical Trials with Companion Diagnostics

When integrating CDx into oncology trials, trial design must reflect the biomarker’s prevalence, predictive power, and the assay’s availability. In an enrichment design, only biomarker-positive patients are enrolled, maximizing effect size but potentially slowing accrual if prevalence is low. An all-comers design with biomarker-stratified analysis allows exploratory evaluation of biomarker-negative patients.

Adaptive designs can allow for mid-trial modifications based on interim biomarker prevalence data, while basket and umbrella trials can leverage a single assay to assign patients to multiple targeted therapies. For example, a comprehensive NGS panel could identify HER2 amplification, BRAF mutations, and RET fusions for allocation to different arms within the same master protocol.

Operationalizing CDx Testing in Trials

Operational success depends on fast turnaround times (TAT) and consistent assay performance across global sites. Establishing a central testing laboratory can standardize results but may increase logistical complexity for sample shipment. Alternatively, a decentralized model with harmonized local labs requires rigorous cross-validation (≥90% concordance with central lab results).

Consent forms must explicitly mention the use of a companion diagnostic, potential incidental findings (e.g., germline BRCA mutations), and data sharing for regulatory purposes. Clinical trial management systems should track test performance metrics, including invalid rates, re-testing frequency, and median TAT.

Reference operational SOPs, such as those available on PharmaGMP.in, to streamline documentation for audits and inspections.

Regulatory Submission and Approval Pathways

The drug and the CDx are often submitted concurrently in a coordinated regulatory package. The FDA requires a premarket approval (PMA) for most CDx devices, while the EMA mandates a CE marking under IVDR rules. Bridging studies may be required if the pivotal trial assay differs from the commercial version, with statistical comparability set at ≥90% concordance.

Post-approval, CDx manufacturers may need to expand the assay’s indications, such as adding ctDNA detection to a tissue-based test. These modifications typically require supplemental PMA submissions or revised technical documentation under IVDR.

Conclusion: Making CDx Work for Precision Oncology

Effective companion diagnostics require early and integrated planning between drug and diagnostic development teams. By aligning regulatory strategies, ensuring rigorous analytical validation, and building operational workflows that can deliver results rapidly and reproducibly, CDx can significantly increase the probability of trial success and regulatory approval. The reward is a therapy that reaches the right patients faster, with robust evidence that the biomarker truly guides treatment benefit.

How Companion Diagnostics Enable Targeted Patient Stratification

Introduction: The Shift Toward Biomarker-Based Stratification

Companion diagnostics (CDx) are revolutionizing the clinical research and therapeutic landscape by enabling targeted patient stratification. No longer is a one-size-fits-all approach acceptable—biomarker-based stratification ensures patients receive therapies tailored to their genetic, proteomic, or molecular profiles. Whether in clinical trials or routine practice, stratification using CDx improves efficacy, reduces adverse effects, and accelerates regulatory approvals.

This article explores the strategic role of CDx in patient stratification, offering clinical examples, assay formats, and trial design frameworks that leverage predictive biomarker insights.

What Is Patient Stratification?

Patient stratification refers to the process of dividing a patient population into subgroups based on specific characteristics—commonly biomarkers, genetic mutations, or protein expression. The goal is to identify which subgroup is more likely to benefit from a given therapy.

• Predictive Biomarkers: Indicate likely response to therapy (e.g., HER2 for trastuzumab efficacy)
• Prognostic Biomarkers: Indicate disease outcome irrespective of treatment (e.g., BRCA1/2 in breast cancer)

Stratification ensures optimized therapeutic selection, enhancing the clinical trial’s statistical power and real-world outcomes.

Role of Companion Diagnostics in Stratification

Companion diagnostics are in vitro assays developed alongside therapeutics. Their role in stratification includes:

• Identifying biomarker-positive patients eligible for a targeted therapy
• Enabling enrichment strategies in clinical trials
• Reducing heterogeneity within treatment arms
• Ensuring regulatory compliance through validated predictive testing

FDA defines a CDx as a device that is essential for the safe and effective use of a corresponding therapeutic product. Its clinical relevance must be demonstrated through co-development with the drug.

Case Study: EGFR Mutation Testing in NSCLC

In non-small cell lung cancer (NSCLC), EGFR mutations (e.g., exon 19 deletions or L858R substitution) serve as predictive biomarkers for tyrosine kinase inhibitors (TKIs) like erlotinib or osimertinib. The cobas® EGFR Mutation Test v2 is an FDA-approved CDx for detecting these mutations.

Patient stratification using this test demonstrated:

• Increased progression-free survival (PFS) in biomarker-positive groups (9.6 months vs 5.2 months)
• Reduced treatment-related toxicities in off-target populations
• Higher trial success rate due to enriched enrollment

Such CDx-driven approaches underscore the power of precision medicine.

Clinical Trial Designs Incorporating Stratification

Clinical trial designs increasingly depend on CDx-based stratification:

• Enrichment Design: Includes only biomarker-positive patients
• Stratified Design: Includes all patients but stratifies randomization by biomarker status
• Adaptive Design: Modifies trial conduct based on interim biomarker response

Example Design Table:

Explore clinical validation approaches at PharmaValidation.in.

Examples of CDx-Enabled Patient Stratification

HER2 Testing in Breast Cancer: HER2 overexpression detected by IHC or FISH identifies candidates for trastuzumab or pertuzumab. Stratification improves outcomes and reduces cardiotoxicity in non-responders.

PD-L1 Expression in Immunotherapy: PD-L1 IHC assays help stratify patients likely to benefit from immune checkpoint inhibitors like pembrolizumab. Various CDx platforms (e.g., 22C3 pharmDx) have different cutoffs and scoring systems.

ALK Rearrangement in NSCLC: ALK-positive patients benefit from crizotinib. FISH-based CDx testing enables rapid identification and treatment decision-making.

In each of these cases, CDx-driven stratification leads to tailored therapy, faster trial recruitment, and reduced patient risk.

Validation of CDx for Stratification

Validation includes demonstrating analytical performance (LOD, LOQ, specificity) and clinical utility. A typical CDx validation dossier contains:

Proper validation ensures that stratification is based on reliable, reproducible data—essential for regulatory approval and patient safety.

Real-World Application of Stratification in Practice

In the post-approval phase, CDx-based stratification is implemented across clinical settings using standardized lab-developed tests (LDTs) or FDA/CE-approved kits. Challenges include:

• Inter-lab variability
• Turnaround time delays
• Cost and reimbursement variability
• Education of clinicians and patients

Despite these, the use of CDx in real-world stratification is expanding—especially with NGS platforms that assess multiple markers in parallel.

Regulatory guidance on stratification implementation is detailed in FDA guidance documents.

Future Trends in CDx-Based Stratification

Emerging trends include:

• Multi-marker Panels: Combining gene expression, mutation, and protein markers
• Liquid Biopsy: Non-invasive CDx testing from plasma ctDNA
• AI-Driven Stratification: Algorithms using real-world data to refine patient subgroups
• Platform-Based CDx: NGS and multiplex PCR-based stratification tools

For example, FoundationOne CDx provides genomic profiling across 300+ genes to stratify patients for over 30 targeted therapies.

Conclusion

Companion diagnostics have become indispensable tools for patient stratification in both clinical trials and routine care. Their ability to predict therapeutic response transforms treatment paradigms, improves patient outcomes, and accelerates drug development. As diagnostic technology advances, the precision and impact of stratification will only deepen—ushering in the next era of truly personalized medicine.